SPECIALTY GUIDELINE MANAGEMENT

INLYTA (axitinib)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

Inlyta is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

B. Compendial Uses

- 1. Relapsed or surgically unresectable stage IV renal cell carcinoma
- 2. Papillary, Hürthle cell, or follicular thyroid carcinoma

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Renal Cell Carcinoma

Authorization of 12 months may be granted for treatment of relapsed, metastatic, or unresectable renal cell carcinoma.

B. Papillary, Hürthe cell, or Follicular Thyroid Carcinoma

Authorization of 12 months may be granted for treatment of papillary, Hürthle cell, or follicular thyroid carcinoma.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

- 1. Inlyta [package insert]. New York, NY: Pfizer Inc., August 2014.
- The NCCN Drugs & Biologics Compendium[®] © 2018 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed May 09, 2018.
- 3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Kidney Cancer. Version 4.2018. Accessed May 09, 2018. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
- 4. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]): Thyroid Carcinoma. Version 4.2018. Accessed May 09, 2018. https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf.

Inlyta 2079-A SGM P2018

© 2018 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.



Reference number 2079-A

Inlyta 2079-A SGM P2018

© 2018 CVS Caremark. All rights reserved.

